Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
PR Newswire Asia
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II..
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II..
DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA..
PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the..